Section Arrow
INTS.NASDAQ
- Intensity Therapeutics
(Financial Status)
Quotes are at least 15-min delayed:2025/07/17 16:43 EDT
After Hours
Last
 0.3344
+0.0009 (+0.27%)
Bid
0.3289
Ask
0.3349
High 0.335 
Low 0.3289 
Volume 25658 
Regular Hours
Last
 0.3335
+0.0082 (+2.52%)
Day High 
0.3395 
Prev. Close
0.3253 
1-M High
0.37099 
Volume 
2.10M 
Bid
0.3289
Ask
0.3349
Day Low
0.321 
Open
0.335 
1-M Low
0.2602 
Market Cap 
8.48M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 0.31 
20-SMA 0.31 
50-SMA 0.39 
52-W High 4.9399 
52-W Low 0.2602 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.05/-0.50
Enterprise Value
8.59M
Balance Sheet
Book Value Per Share
0.01
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
WINTWindtree Therapeutics Inc.1.05+0.15+16.67%0.84PE
After Hours 1.1 +0.05 +4.76%
ABPAbpro Holdings Inc0.1962-0.022-10.08%-- 
After Hours 0.1957 -0.0005 -0.25%
NCNANuCana plc0.0468-0.0034-6.77%-- 
After Hours 0.0469 +0.0001 +0.21%
ATNF180 Life Sciences Corp1.83+0.9497+107.88%0.11PE
After Hours 1.71 -0.12 -6.56%
MRKRMarker Therapeutics1.92+0.32+20.00%-- 
After Hours 1.92 0 0.00%
Quotes are at least 15-min delayed:2025/07/17 16:43 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with unmet medical need.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.